Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, interstitial lung diseases, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and primary biliary cholangitis.
Scientists at Helmholtz Zentrum für Infektionsforschung GmbH, Rijksuniversiteit Groningen and Université de Lausanne have synthesized energy-coupling factor (ECF) transporter (bacterial) inhibitors reported to be useful for the treatment of enterococcal and streptococcal infections.
Maplight Therapeutics Inc. has disclosed G protein-coupled receptor GPR52 modulators reported to be useful for the treatment of neurological and psychiatric disorders.
Work at Sensorium Therapeutics Inc. has led to the identification of new serotonin transporter (SERT) inhibitors reported to be useful for the treatment of depression, anxiety and stress disorders.
A Raythera Inc. patent describes tyrosine-protein kinase JAK2 (V617F mutant) inhibitors or degraders reported to be useful for the treatment of cancer.
Rgenta Therapeutics Inc. has synthesized new 2,3-dihydropyrollopyridine carboxamide compounds acting as PMS1 protein homolog 1 splicing modulators. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, Friedreich ataxia, myotonic dystrophy, fragile X syndrome, frontotemporal dementia, Fuchs dystrophy, Huntington’s disease and spinal and bulbar muscular atrophy, among others.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Work at Emory University has led to the development of peptidomimetic compounds acting as protease (viral) inhibitors reported to be useful for the treatment of viral infections.